Tazemetostat (EPZ6438) is a histone methyltransferase EZH2 inhibitor (IC50=11 nM) that is orally active, selective, and SAM-competitive. Tazemetostat exhibits antitumor activity and may be used for the treatment of epithelioid sarcoma/follicular lymphoma.

EZH2:2.5 nM(Ki)

方法：滑膜肉瘤细胞 Fuji 和 HS-SY-II 用 Tazemetostat (0.039-20 µmol/L) 处理 14 天，使用 CellTiter-Glo Luminescent Cell Viability Assay 检测细胞活力。
结果：Tazemetostat 处理 Fuji 和 HS-SY-II 细胞增殖的浓度依赖性降低，IC50 值分别为 0.15 µmol/L 和 0.52 µmol/L。[1]
方法：人肾癌细胞 G401 和人恶性胚胎横纹肌瘤细胞 RD 用 Tazemetostat (0.006-1100 nM) 处理 4 天，使用 Western Blot 方法检测靶点蛋白表达水平。
结果：Tazemetostat 处理导致整体 H3K27Me3 水平的浓度依赖性降低。[2]

方法：为检测体内抗肿瘤活性，将 Tazemetostat (125-500 mg/kg，0.5% NaCMC plus 0.1% Tween 80 in water) 口服给药给携带人肾癌肿瘤 G401 的 SCID 小鼠，每天两次，持续二十八天。
结果：Tazemetostat 导致 SMARCB1突变型 MRT 异种移植物完全和持续消退。[1]
方法：为研究在蛛网膜下腔出血 (SAH) 诱导的神经炎症中的作用，将 Tazemetostat (1-9 mg/kg) 腹腔注射给血管内穿孔法诱导蛛网膜下腔出血的大鼠模型。
结果：Tazemetostat 对 EZH2 的抑制通过 H3K27me3/SOCS3/TRAF6/NF-κB 信号通路减轻了大鼠 SAH 后的神经炎症。[3]

Biochemical Methods: EPZ-6438 is incubated for 30 min with 40 μL per well of 5 nM PRC2 (final assay concentration in 50 μL is 4 nM ) in 1X assay buffer (20 mM Bicine [pH 7.6], 0.002% Tween-20, 0.005% Bovine Skin Gelatin and 0.5 mM DTT). 10 μL per well of substrate mix comprising assay buffer 3 H-SAM, unlabeled SAM, and peptide representing histone H3 residues 21-44 containing C-terminal biotin (appended to a C-terminal amide-capped lysine) are added to initiate the reaction (both substrates are present in the final reaction mixture at their respective Km values, an assay format referred to as ‘‘balanced conditions''. The final concentrations of substrates and methylation state of the substrate peptide are indicated for each enzyme Reactions are incubated for 90 min at room temperature and quenched with 10 μL per well of 600 μM unlabeled SAM, Then transferred to a 384-well flashplate and washed after 30 min.

For the adherent cell line proliferation assays, plating densities for each cell line are determined based on growth curves (measured by ATP content) and density over a 7-d time course. On the day before compound treatment, cells are plated in either 96-well plates in triplicate (for the day 0–7 time course) or 6-well plates (for replating on day 7 for the remainder of the time course). On day 0, cells are either untreated, DMSO-treated, or treated with EPZ-6438 starting at 10 μM and decreasing in either threefold or fourfold dilutions. Plates are read on day 0, day 4, and day 7 using Cell Titer Glo, with compound/media being replenished on day 4. On day 7, the six-well plates are trypsinized, centrifuged, and resuspended in fresh media for counting by Vi-Cell. Cells from each treatment are replated at the original density in 96-well plates in triplicate. Cells are allowed to adhere to the plate overnight, and cells are treated as on day 0. On days 7, 11, and 14, plates are read using Cell Titer Glo, with compound/media being replenished on day 11. Averages of triplicates are used to plot proliferation over the time course, and calculate IC50 values. For cell cycle and apoptosis, G401 and RD cells are plated in 15-cm dishes in duplicate at a density of 1 × 106 cells per plate. Cells are incubated with EPZ-6438 at 1 μM, in a total of 25 mL, over a course of 14 d, with cells being split back to original plating density on day 4, 7, and 11. Cell cycle analysis and TUNEL assay are performed using a Guava flow cytometer, following the manufacturer's protocol.(Only for Reference)